• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens.

作者信息

Botta Cirino, Martino Enrica Antonia, Conticello Concetta, Mendicino Francesco, Vigna Ernesto, Romano Alessandra, Palumbo Giuseppe Antonio, Cerchione Claudio, Martinelli Giovanni, Morabito Fortunato, Di Raimondo Francesco, Gentile Massimo

机构信息

Hematology Unit, "Annunziata" Hospital of Cosenza, Cosenza, Italy.

Division of Hematology, AOU Policlinico, Catania, Italy.

出版信息

Front Oncol. 2021 Apr 14;11:643490. doi: 10.3389/fonc.2021.643490. eCollection 2021.

DOI:10.3389/fonc.2021.643490
PMID:33937048
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8079718/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd9f/8079718/26be1484ff04/fonc-11-643490-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd9f/8079718/26be1484ff04/fonc-11-643490-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd9f/8079718/26be1484ff04/fonc-11-643490-g001.jpg

相似文献

1
Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens.来那度胺暴露或难治性多发性骨髓瘤的治疗：来那度胺减量方案的网状Meta分析
Front Oncol. 2021 Apr 14;11:643490. doi: 10.3389/fonc.2021.643490. eCollection 2021.
2
Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib.针对来那度胺和硼替佐米耐药的多发性骨髓瘤患者，CD38 靶向免疫化疗的治疗潜力的临床前证据。
Clin Cancer Res. 2015 Jun 15;21(12):2802-10. doi: 10.1158/1078-0432.CCR-14-1813. Epub 2014 Nov 14.
3
Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma.达雷妥尤单抗联合卡非佐米和地塞米松治疗复发或难治性多发性骨髓瘤患者。
Blood. 2019 Aug 1;134(5):421-431. doi: 10.1182/blood.2019000722. Epub 2019 May 21.
4
Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments.达雷妥尤单抗用于初诊及复发/难治性多发性骨髓瘤的治疗：当前及新出现的疗法
Front Oncol. 2021 Feb 17;10:624661. doi: 10.3389/fonc.2020.624661. eCollection 2020.
5
Treatment Outcomes in Patients With Newly Diagnosed Multiple Myeloma Who Are Ineligible for Stem-Cell Transplantation: Systematic Review and Network Meta-analysis.不适合干细胞移植的新诊断多发性骨髓瘤患者的治疗结局：系统评价和网络荟萃分析。
Clin Lymphoma Myeloma Leuk. 2019 Aug;19(8):e478-e488. doi: 10.1016/j.clml.2019.04.009. Epub 2019 Apr 29.
6
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study.卡非佐米、地塞米松和达雷妥尤单抗与卡非佐米和地塞米松治疗复发或难治性多发性骨髓瘤患者（CANDOR）：一项随机、多中心、开放性、3 期研究的结果。
Lancet. 2020 Jul 18;396(10245):186-197. doi: 10.1016/S0140-6736(20)30734-0.
7
A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma.isatuximab联合来那度胺及地塞米松治疗复发/难治性多发性骨髓瘤的1b期研究
Blood. 2017 Jun 22;129(25):3294-3303. doi: 10.1182/blood-2016-09-740787. Epub 2017 May 8.
8
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.来那度胺治疗后复发或难治性多发性骨髓瘤患者的泊马度胺、硼替佐米和地塞米松治疗（OPTIMISMM）：一项随机、开放标签、3 期试验。
Lancet Oncol. 2019 Jun;20(6):781-794. doi: 10.1016/S1470-2045(19)30152-4. Epub 2019 May 13.
9
A Comparison of the Efficacy of Immunomodulatory-containing Regimens in Relapsed/Refractory Multiple Myeloma: A Network Meta-analysis.含免疫调节方案治疗复发/难治性多发性骨髓瘤的疗效比较：一项网状Meta分析
Clin Lymphoma Myeloma Leuk. 2018 Mar;18(3):163-173.e6. doi: 10.1016/j.clml.2017.12.011. Epub 2018 Jan 5.
10
Estimating the Costs of Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma: A Model Framework.评估复发和/或难治性多发性骨髓瘤患者的治疗成本：一个模型框架。
Am Health Drug Benefits. 2015 Jun;8(4):204-15.

引用本文的文献

1
A network meta-analysis of randomized clinical trials in lenalidomide-exposed or -refractory multiple myeloma patients.来那度胺治疗的或难治性多发性骨髓瘤患者随机临床试验的网络荟萃分析。
ESMO Open. 2025 Jul 15;10(8):105514. doi: 10.1016/j.esmoop.2025.105514.
2
Analysis of pharmacotherapeutic approaches for multiple myeloma and correlated renal and pulmonary impairments: a retrospective real-world registry study in the Greater Gulf Region (REPAIR Study).多发性骨髓瘤及相关肾肺损伤的药物治疗方法分析：大湾地区的一项回顾性真实世界注册研究（REPAIR研究）
Front Oncol. 2025 May 9;15:1547138. doi: 10.3389/fonc.2025.1547138. eCollection 2025.
3

本文引用的文献

1
Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse.泊马度胺、硼替佐米和地塞米松治疗来那度胺预处理的多发性骨髓瘤（OPTIMISMM）：首次复发时的既往治疗结果。
Leukemia. 2021 Jun;35(6):1722-1731. doi: 10.1038/s41375-020-01021-3. Epub 2020 Sep 7.
2
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study.卡非佐米、地塞米松和达雷妥尤单抗与卡非佐米和地塞米松治疗复发或难治性多发性骨髓瘤患者（CANDOR）：一项随机、多中心、开放性、3 期研究的结果。
Lancet. 2020 Jul 18;396(10245):186-197. doi: 10.1016/S0140-6736(20)30734-0.
3
Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study.
isatuximab、卡非佐米和地塞米松（IsaKd）用于自体干细胞移植和来那度胺维持治疗后首次复发的多发性骨髓瘤患者的疗效和安全性：多中心、真实世界AENEID研究结果
Pharmaceuticals (Basel). 2025 Apr 19;18(4):595. doi: 10.3390/ph18040595.
4
Efficacy of CARVYKTI in CARTITUDE-4 versus other conventional treatment regimens for lenalidomide-refractory multiple myeloma using inverse probability of treatment weighting.使用逆概率治疗加权法比较 CARVYKTI 在 CARTITUDE-4 与其他用于来那度胺难治性多发性骨髓瘤的常规治疗方案的疗效。
J Comp Eff Res. 2024 Sep;13(9):e240080. doi: 10.57264/cer-2024-0080. Epub 2024 Aug 20.
5
Multiple Myeloma in 2023 Ways: From Trials to Real Life.2023 年多发性骨髓瘤的多种治疗方法：从临床试验到现实生活。
Curr Oncol. 2023 Nov 3;30(11):9710-9733. doi: 10.3390/curroncol30110705.
6
A real-life study of daratumumab-bortezomib-dexamethasone (D-VD) in lenalidomide exposed/refractory multiple myeloma patients: a report from the Triveneto Myeloma Working Group.达雷妥尤单抗联合硼替佐米和地塞米松（D-VD）治疗(lenalidomide 暴露/难治)多发性骨髓瘤患者的真实世界研究：来自特伦托骨髓瘤工作组的报告。
Ann Hematol. 2024 Jan;103(1):125-132. doi: 10.1007/s00277-023-05443-8. Epub 2023 Sep 20.
7
Molecular-Biology-Driven Frontline Treatment for Chronic Lymphocytic Leukemia: A Network Meta-Analysis of Randomized Clinical Trials.基于分子生物学的慢性淋巴细胞白血病一线治疗：随机临床试验的网络荟萃分析。
Int J Mol Sci. 2023 Jun 9;24(12):9930. doi: 10.3390/ijms24129930.
8
How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma.如何管理来那度胺难治性多发性骨髓瘤患者。
Cancers (Basel). 2022 Dec 27;15(1):155. doi: 10.3390/cancers15010155.
9
Network meta-analysis of randomized trials in multiple myeloma: Efficacy and safety in frontline therapy for patients not eligible for transplant.随机临床试验的网络荟萃分析：不适合移植的多发性骨髓瘤患者一线治疗的疗效和安全性。
Hematol Oncol. 2022 Dec;40(5):987-998. doi: 10.1002/hon.3041. Epub 2022 Jul 11.
10
Carfilzomib plus dexamethasone in patients with relapsed and refractory multiple myeloma: A retro-prospective observational study.卡非佐米联合地塞米松治疗复发/难治性多发性骨髓瘤患者：一项回顾性前瞻性观察研究。
Eur J Haematol. 2022 Oct;109(4):373-380. doi: 10.1111/ejh.13819. Epub 2022 Jul 13.
miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma.miR-21 拮抗作用可消除多发性骨髓瘤中 Th17 肿瘤促进功能。
Leukemia. 2021 Mar;35(3):823-834. doi: 10.1038/s41375-020-0947-1. Epub 2020 Jul 6.
4
Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment.来那度胺治疗后复发/难治性多发性骨髓瘤患者采用泊马度胺、地塞米松和达雷妥尤单抗治疗。
Leukemia. 2020 Dec;34(12):3286-3297. doi: 10.1038/s41375-020-0813-1. Epub 2020 May 6.
5
Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma.免疫基因组学鉴定和多发性骨髓瘤中粒细胞髓系来源抑制细胞的特征。
Blood. 2020 Jul 9;136(2):199-209. doi: 10.1182/blood.2019004537.
6
Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone.来那度胺末次剂量、持续时间和 IMiD 无治疗间期对接受泊马度胺/地塞米松治疗的骨髓瘤患者的影响。
Blood Adv. 2019 Dec 10;3(23):4095-4103. doi: 10.1182/bloodadvances.2019000539.
7
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.依沙佐米联合泊马度胺和低剂量地塞米松与泊马度胺和低剂量地塞米松治疗复发/难治性多发性骨髓瘤患者（ICARIA-MM）：一项随机、多中心、开放性、3 期研究。
Lancet. 2019 Dec 7;394(10214):2096-2107. doi: 10.1016/S0140-6736(19)32556-5. Epub 2019 Nov 14.
8
Expert Panel Consensus Statement for Proper Evaluation of First Relapse in Multiple Myeloma.多发性骨髓瘤首次复发的正确评估专家小组共识声明。
Curr Hematol Malig Rep. 2019 Jun;14(3):187-196. doi: 10.1007/s11899-019-00507-x.
9
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma.盐酸拓扑替康直接诱导和自然杀伤细胞介导的多发性骨髓瘤细胞毒性作用。
J Hematol Oncol. 2019 Mar 21;12(1):32. doi: 10.1186/s13045-019-0714-9.
10
Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.埃罗妥珠单抗联合泊马度胺和地塞米松治疗多发性骨髓瘤。
N Engl J Med. 2018 Nov 8;379(19):1811-1822. doi: 10.1056/NEJMoa1805762.